Today is an exciting and transformative day for Jazz Pharmaceuticals as we complete the acquisition of GW Pharmaceuticals and its U.S. subsidiary, Greenwich Biosciences, a world leader in the science, development and commercialization of regulatory approved cannabinoid medicines.
With more than two decades spent pioneering cannabinoid science, GW Pharmaceuticals CEO Justin Gover and his team have built an impressive commercial portfolio and innovative pipeline of early and late-stage product candidates. Through this acquisition, we’re establishing a more robust and diversified focus across neuroscience and bringing together highly complementary expertise across sleep, epilepsies, movement disorders and psychiatry.
While this integration will not drive major changes in our day-to-day work, we welcome the opportunities it presents to have a positive impact on patients. Our teams share aligned cultures and are working collaboratively to ensure that the combined company leverages the strengths of both Jazz and GW so that we can build on our purpose to innovate to transform the lives of patients and their families, as well as to foster a great place to work for our employees.
Through the integration, our top priority is fulfilling our responsibility to patients and customers, and we remain committed to the therapeutic areas we have been focused on across Jazz and GW. Our combined organization will continue to focus on patients with high unmet needs and pursue innovative and differentiated therapies that establish new or better standards of care in neuroscience and oncology. With the addition of GW Pharmaceuticals, Jazz now has the world’s leading cannabinoid research platform and will continue development efforts to further evaluate cannabinoid science in new neuroscience areas of focus.
I’d like to say a big thank you to each of the team members across both organizations who have had a hand in preparing for an integration that minimizes disruption and creates a seamless experience patients, providers and payors; and ensures a great employee experience.
As we break ground with new medicines and look to meet the needs of more patients in the future, we remain as committed as ever to those we serve today. We feel fortunate to be combining two companies with a shared passion for, and track record of, developing differentiated therapies that advance science and transform the lives of patients and families around the world.
To learn more about the acquisition, visit: http://investor.jazzpharma.com/news?c=210227&p=irol-newsPage
